© 2015

The Future of HIV-1 Therapeutics

Resistance Is Futile?

  • Bruce E. Torbett
  • David S. Goodsell
  • Douglas D. Richman


  • Highlights the identification and evaluation of antiretrovirals that may be less prone in selecting for HIV-1 resistance

  • Covers recent advances in the identification and function of small molecule inhibitors that target novel HIV-1 regulatory and structural components to disrupt replication and alter the state of viral latency

  • Offers up-to-date information for virologists, infectious disease specialists, and chemical biologists on HIV-1 antiretrovirals currently in use


Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 389)

Table of contents

  1. Front Matter
    Pages i-x
  2. David Looney, Ariel Ma, Scott Johns
    Pages 1-29
  3. Mattia Mori, Lesia Kovalenko, Sébastien Lyonnais, Danny Antaki, Bruce E. Torbett, Maurizio Botta et al.
    Pages 53-92
  4. Lei Feng, Ross C. Larue, Alison Slaughter, Jacques J. Kessl, Mamuka Kvaratskhelia
    Pages 93-119
  5. Guillaume Mousseau, Sonia Mediouni, Susana T. Valente
    Pages 121-145
  6. Philip R. Tedbury, Eric O. Freed
    Pages 171-201
  7. Marc Potempa, Sook-Kyung Lee, Richard Wolfenden, Ronald Swanstrom
    Pages 203-241
  8. David S. Goodsell
    Pages 243-252
  9. Back Matter
    Pages 253-254

About this book


This volume thoroughly covers HIV-1 antiretrovirals currently in clinical use, together with their advantages and limitations. HIV-1 inhibitor resistance is discussed in detail, and critical assessments as to what will be required of future antiretrovirals in order to halt viral replication, reduce viral resistance, and alter the state of viral latency are presented. Experts at the forefront of HIV-1 research provide overviews of approaches from the fields of virology, chemical biology and structural biology for obtaining small molecule inhibitors that target viral regulatory and structural components at multiple points in the viral lifecycle. The individual chapters will appeal to scientists and clinicians alike.


Fragment-based drug design HIV Gag protein HIV capsid HIV integrase protein HIV matrix HIV nucleocapsid protein HIV protease HIV reverse transcriptase protein HIV stem-loop HIV transcription HIV-1 antiretroviral treatment HIV-1 drug resistance HIV-1 illustrations HIV-1 latency High-throughput virtual screening Human immunodeficiency virus LEDGF/p75 protein Rev protein Structure-based drug design Tat/TAR/P-TEFb complex

Editors and affiliations

  • Bruce E. Torbett
    • 1
  • David S. Goodsell
    • 2
  • Douglas D. Richman
    • 3
  1. 1.Departments of Molecular and Experimental Medicine and Immunology and Microbial Science (MEM 131)The Scripps Research InstituteLa JollaUSA
  2. 2.Department of Integrative Structural and Computational Biology, and RCSB Protein Data BankThe Scripps Research InstituteLa JollaUSA
  3. 3.Department of PathologyUniversity of California, San DiegoLa JollaUSA

Bibliographic information

  • Book Title The Future of HIV-1 Therapeutics
  • Book Subtitle Resistance Is Futile?
  • Editors Bruce E. Torbett
    David S. Goodsell
    Douglas D. Richman
  • Series Title Current Topics in Microbiology and Immunology
  • Series Abbreviated Title Current Topics in Microbiology and Immunology
  • DOI
  • Copyright Information Springer International Publishing Switzerland 2015
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences Biomedical and Life Sciences (R0)
  • Hardcover ISBN 978-3-319-18517-0
  • Softcover ISBN 978-3-319-37450-5
  • eBook ISBN 978-3-319-18518-7
  • Series ISSN 0070-217X
  • Series E-ISSN 2196-9965
  • Edition Number 1
  • Number of Pages X, 254
  • Number of Illustrations 0 b/w illustrations, 0 illustrations in colour
  • Topics Drug Resistance
    Infectious Diseases
  • Buy this book on publisher's site
Industry Sectors


“The book does a fantastic job of addressing new approaches to inhibit HIV-1. … this is a useful book that can be used by researchers, HIV clinicians, and medicinal chemists interested in investigating new molecules for the treatment of HIV-1. It addresses novel areas that have no chemical entities that are FDA approved. There are no books that compete with this one.” (Christopher J. Destache, Doody's Book Reviews, September, 2015)

“This book includes 8 comprehensive, heavily referenced chapters on antiretroviral drug development. … a comprehensive, readable review of a subject that brings together 2 or more decades of molecular virology research and drug development. … the chapters in this book are likely to be, for the next several years, highly useful and popular starting points for learning about new areas in HIV drug development.” (Robert W. Shafer, Clinical Infectious Diseases, September, 2015)